Microsphere Localization Using Image Result for Positron Emission Tomography-Magnetic Resonance Imaging (PET/MRI) or Positron Emission Tomography-Computed Tomography (PET/CT) in Patients With Liver Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2016 by Washington University School of Medicine
Sponsor:
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01744054
First received: November 30, 2012
Last updated: December 7, 2016
Last verified: December 2016
  Purpose
The successful localization of the y90 microspheres by PET/MR and/or PET/CT scans would be a useful tool in individualizing patient care after the radioembolization procedure. The information from a PET/MR or PET/CT scan would allow for early evaluation of the technical success of the procedure.

Condition Intervention Phase
Liver Neoplasms
Device: PET/MR
Device: PET/CT
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Pilot Study of Microsphere Localization Using PET/MRI or PET/CT in Patients With Liver Disease Following Radioembolization

Resource links provided by NLM:


Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • Evaluate y90-PET/MRI and PET/CT for potential on reporting presence of extrahepatic deposition of microspheres [ Time Frame: 1 day (one time event for patient) ]
    A diagnostic radiologist and a nuclear medicine physician will evaluate the images and will determine any presence of extrahepatic deposition of microspheres.

  • Evaluate y90-PET/MRI and PET/CT for potential on reporting technical success of radioembolization [ Time Frame: 1 day (one time event for patient) ]
    A diagnostic radiologist and a nuclear medicine physician will evaluate the images and will determine whether technical success of the procedure can be determined. They will rate the images if they are 'adequate' to report on these two measures.


Estimated Enrollment: 60
Study Start Date: October 2012
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
PET/MR or PET/CT
  • Patients must have had radioembolization, within 72 hours of the PET/MR or PET/CT
  • Subjects will be asked to lie still within the scanner for up to 1.5 hours while images are acquired for the liver
Device: PET/MR Device: PET/CT

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant must successfully complete the MRI screening form if receiving an MRI
  • Participant must be scheduled to undergo radioembolization for any indication
  • Participant must be ≥ 18 years of age
  • Participant must be able to understand and willing to sign an Institutional Review Board (IRB)-approved written informed consent document

Exclusion Criteria:

  • Participant must not have any contraindications to MRI scanning
  • Patient must not be pregnant or breastfeeding
  • If agreeing to MRI contrast, participant must not have renal insufficiency (glomerular filtration rate (GFR < 30 mL/min/1.73 m2) measured within the past 60 days
  • If agreeing to MRI contrast, participant must not be on dialysis
  • If agreeing to MRI contrast, participant must not have had a prior allergic reaction to gadolinium-based contrast agents
  • PET/MRI or PET/CT is not able to be scheduled within 72 hours of radioembolization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01744054

Contacts
Contact: Parag Parikh, M.D. 314-747-9614 parikh@wustl.edu

Locations
United States, Missouri
Washington University School of Medicine Recruiting
St. Louis, Missouri, United States, 63122
Contact: Parag Parikh, M.D.    314-747-9614    parikh@wustl.edu   
Sub-Investigator: Kathryn Fowler, M.D.         
Sub-Investigator: Richard LaForest, PhD         
Sub-Investigator: Jose Garcia-Ramirez, M.S         
Sub-Investigator: Nael Saad, M.D.         
Sub-Investigator: Todd DeWees, Ph.D.         
Sponsors and Collaborators
Washington University School of Medicine
Investigators
Principal Investigator: Parag Parikh, M.D. Washington University School of Medicine
  More Information

Additional Information:
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT01744054     History of Changes
Other Study ID Numbers: 201209062 
Study First Received: November 30, 2012
Last Updated: December 7, 2016
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Liver Diseases
Liver Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Neoplasms by Site
Neoplasms

ClinicalTrials.gov processed this record on January 19, 2017